(CercleFinance.com) – Biophytis recorded one of the strongest rises on the Paris Stock Exchange on Thursday, the market welcoming the complete results of a phase 2-3 study in severe forms of Covid-19.
Around 12:00 p.m., the biotechnology company title wins more than 24
% while the Euronext Growth All-Share index lost 1%.
According to Biophytis, the conclusions of the trial – which aimed to assess the efficacy and safety of Sarconeos (BIO101) in hospitalized Covid patients at risk of respiratory failure – “strongly” support the therapeutic potential of the tablet.
With regard to respiratory failure or early death, post-hoc analyzes show a reduction of between 45% and 53% in risk after 28 days, a performance described as ‘impressive’ by the company.
Biophytis indicates that these results “above expectations” encourage it to continue the development of the molecule in this indication, with the objective of filing a marketing authorization application in 2023.
The action is still down nearly 85% since the start of the year.